Study Evaluating the Efficacy and Safety of Artesunate

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

June 30, 2028

Conditions
CMV Infection
Interventions
DRUG

Artesunate

Low Dose Artesunate: 2.4 mg/kg IV artesunate once daily for 14 days + GCV or VGCV and SOC per local institutional practices High Dose Artesunate: 4.8 mg/kg IV artesunate once daily for 14 days + GCV or VGCV and SOC per local institutional practices

DRUG

Ganciclovir (GCV)

Standard Treatment Ganciclovir: GCV or VGCV and SOC per local institutional practices

Trial Locations (2)

Unknown

RECRUITING

Westmead Hospital, Westmead

RECRUITING

Princess Alexandra Hospital, Woolloongabba

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amivas Inc.

INDUSTRY

NCT06853184 - Study Evaluating the Efficacy and Safety of Artesunate | Biotech Hunter | Biotech Hunter